AACR 2019

...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Reply New Message

Prev Message Back To Forum Threaded View Next Message

BearDownAZ

Rank: President [?]

Points: 25003 [?]

Votes: 68 Score: 4.5 [?]

Your Vote:

Please Log In to Vote

Did you know? You can earn activity points by filling your profile with information about yourself (what city you live in, your favorite team, blogs etc.)

AACR 2019

posted on Feb 27, 2019 10:45PM

AACR 2019, March 29 to April 3, 2019 in Atlanta, Georgia. Clinical Trial and Late-Breaking Abstract Titles Posted to Online Itinerary Planner today. Poster session April 1. No abstract available yet.

CT095. A Phase Ib/IIa study of the BET bromodomain inhibitor ZEN-3694 in combination with enzalutamide in patients with metastatic castration-resistant prostate cancer (mCRPC)

4 Recommendations

Reply New Message

Prev Message Back To Forum Threaded View Next Message

Please to post a reply